The newest weight-loss drugs, Wegovy and Zepbound, are incredibly popular. But doctors are still learning about all of the ...

A high dose of Novo Nordisk’s obesity drug Wegovy led patients to lose substantial weight in a clinical trial, but still less ...

Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ...

Novo Nordisk said patients taking a bigger dose of its blockbuster obesity drug lost more weight than those on a lower dose, ...

Millions of Brits are now eligible for the appetite-suppressing jabs which can come with unpleasant side effects - but NHS rationing means only a tiny fraction will be prescribed them ...

Novo Nordisk said a higher dose of its drug Wegovy led to greater weight loss in patients during a late-stage trial, but the ...

One of Novo Nordisk's next-generation obesity shots to follow up on the success of Wegovy helped patients lose 22% of their ...

Wegovy, the weight-loss brand of semaglutide, has a recommended maintenance dose of 2.4 mg. Novo ran the Phase III STEP UP ...

A new study conducted by researchers from the University of Eastern Finland the Karolinska Institutet explored the ways that ...

Its weight-loss drug policy would fall to Trump's pick for health secretary, Robert F Kennedy Jr, and Mehmet Oz, Trump's ...

News research shows GLP-1 medications may help treat a wide range of conditions, from addiction and dementia to heart disease ...

Federal officials are targeting the blockbuster drugs as part of their ongoing initiative to lower drug costs.